NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Medical Instruments & Supplies · USD

Bausch + Lomb Corporation (BLCO) Stock Analysis

Bausch + Lomb Corporation (BLCO) is a Medical Instruments & Supplies stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

BLCO

$17.18

+$0.25 (+1.48%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BLCO with… →

BLCO Key Statistics

As of Oct 21, 2026
Trading
Open
$16.89
Previous Close
$16.93
Day's Range
16.68–17.24
52-Week Range
14.44–18.92
Volume
437.98K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.56
Valuation
Market Cap
$5.73B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
14.40
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.89
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.08
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.49
Financials (FY)
Revenue (FY)
$5.10B+6.47%
Net Income (FY)
−$360.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
−3.21%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
357.17M
1-Year Return
+9.92%
Dividend and dates
Earnings Date
October 28, 2026
Avg Volume
442.01K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BLCO closed at $17.18, +9.92% over 1 year.

Bausch + Lomb Corporation (BLCO) has a market capitalization of $5.73B.

In fiscal 2025, BLCO reported revenue of $5.10B.

BLCO Stock Return by Calendar Year

Bausch + Lomb Corporation (BLCO) return since May 2022: what $10,000 became

1 year
$10,000 $10,992
+9.92%
3 years
$10,000 $10,160
+1.60%
Since May 2022
$10,000 $8,590
−14.10%

If you had invested $10,000 in Bausch + Lomb Corporation (BLCO) at the close on May 6, 2022, the earliest close on record here, it would have been worth $8,590 at the close on October 21, 2026: −14.10% in total, −3.35% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.59%
2025−5.43%
2024+5.86%
2023+9.99%
2022 (partial year)−22.45%

As of October 21, 2026.

BLCO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$5.10B−$360.00M−7.1%
2024$4.79B−$317.00M−6.6%
2023$4.15B−$260.00M−6.3%
2022$3.77B$6.00M0.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$5.10B$3.05B$188.00M−$360.00M−7.1%
2024$4.79B$2.92B$206.00M−$317.00M−6.6%
2023$4.15B$2.50B$204.00M−$260.00M−6.3%
2022$3.77B$2.25B$220.00M$6.00M0.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BLCO Valuation vs Medical Instruments & Supplies Median

Median of 50 stocks
MetricBLCOMedical Instruments & Supplies medianvs median
P/S ratio1.082.6059% below
Profit margin−3.21%1.62%4.8 pts below

Medians across 50 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Bausch + Lomb Corporation (BLCO) is capitalised at $5.73B on the latest close. It is classified in the Medical Instruments & Supplies industry, within the Healthcare sector. The company reports 13,000 employees.

Over the past 52 weeks the price has ranged from $14.44 to $18.92. The most recent close on file for BLCO is $17.18, dated October 21, 2026. That is +$0.25 (+1.48%) against the previous close. The latest close sits 18.98% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $5.10B. That is +6.47% against the prior fiscal year, when revenue was $4.79B. The same year closed with a net loss of $360.00M. Profit margin runs at −3.21%. That is 4.8 percentage points below the Medical Instruments & Supplies median of 1.62%. Earnings per share on a trailing basis come to −0.49.

Across the 4 fiscal years on file, revenue moves from $3.77B in 2022 to $5.10B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 14.4. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.89. The price-to-sales ratio is 1.08. On price-to-sales that is 58.58% below the Medical Instruments & Supplies median of 2.6. The medians here are taken across 50 Medical Instruments & Supplies companies that report the metric.

Over the trailing twelve months the total return is +9.92%. Across 3 years the annualized return works out at +0.53%. The reported beta is 0.56. Annualized volatility over the trailing 4 years is 37.19%.

Growth & Income

The record shows no dividend for BLCO.

The strongest complete calendar year on file is 2023 at +9.99%; the weakest is 2025 at −5.43%. Of the 3 complete calendar years on file, 2 finished higher. So far in 2026 the total return is +0.59%.

Peer Comparison

Bausch + Lomb Corporation (BLCO) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bausch + Lomb Corporation BLCO $5.73B —
Intuitive Surgical, Inc. ISRG $151.25B 51.8
Becton, Dickinson and Company BDX $52.79B 45.1
Medline Inc. MDLN $47.51B 88.3

The Medical Instruments & Supplies industry average P/E ratio is 31.2x. Bausch + Lomb Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$151.25B

 BDX

Becton, Dickinson and Company

$52.79B

 MDLN

Medline Inc.

$47.51B

 RMD

ResMed Inc.

$34.63B

 ALC

Alcon Inc.

$32.60B

 WST

West Pharmaceutical Services, Inc.

$27.69B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Bausch + Lomb Corporation

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Visit website →